Effects of 1,7-Substituted Methylxanthine Derivatives on LPS-Stimulated Expression of Cytokines and Chemokines in Raw 264.7 and HK-2 Cells

被引:8
作者
Kang, Joo-Yeon [1 ]
Shin, Hea-Soon [1 ]
机构
[1] Duksung Womens Univ, Coll Pharm, Seoul 132714, South Korea
关键词
Anti-inflammatory effect; pentoxifylline; pro-inflammatory cytokine; WHOLE-BLOOD; PENTOXIFYLLINE; INHIBITION;
D O I
10.4014/jmb.1410.10044
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Chronic kidney diseases are based on uncontrolled immunological and inflammatory responses to pathophysiological renal circumstances such as glomerulonephritis, which is caused by immunological mechanisms of glomerular inflammation with increased production of renal pro-inflammatory cytokines. Pentoxifylline (PTX) exhibits anti-inflammatory properties by inhibiting cytokine and chemokine production through aggregation of erythrocytes and thrombocytes. We synthesized a series of 1,7-substituted methylxanthine derivatives by the Traube purine reaction, and the formation of purine ring was completed through nitrosation, a reduction of the nitroso to the amine by catalytic hydrogenation as derivatives of PTX. Then we studied biological activities such as renal anti-inflammatory effects of the synthesized compounds in the production of cytokines such as nitric oxide (NO), interleukin (IL)-1 beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha) and of chemokines such as monocyte chemoattractant protein-1 and IL-8 in Raw 264.7 and HK-2 cells. Renal anti-inflammatory activities of this novel series of N-1 and N-7-substituted methylxanthine showed that the N-7 methyl-group-substituted analogs (S7b) showed selective 61% and 77% inhibition of the production of NO and IL-8. The other replacement of the N-1-(CH2)(4)COCH3 group, as in the case of compound S6c, also showed an effective 50% and 77% inhibition of TNF-a and IL-8 production in LPS-stimulated Raw 264.7 and HK-2 cells.
引用
收藏
页码:296 / 301
页数:6
相关论文
共 19 条
[1]   Pentoxifylline attenuates the increase in whole blood viscosity after transfusion [J].
Bacher, A ;
Eggensperger, E ;
Koppensteiner, R ;
Mayer, N ;
Klimscha, W .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2005, 49 (01) :41-46
[2]  
Berk Barkin, 2005, Farmaco (Lausanne), V60, P974, DOI 10.1016/j.farmac.2005.08.011
[3]   Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline [J].
Bhat, VB ;
Madyastha, KM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 288 (05) :1212-1217
[4]   Influence of pentoxifylline, A-802710, propentofylline and A-802715 (Hoechst) on the expression of cell cycle blocks and S-phase content after irradiation damage [J].
Bohm, L ;
Theron, T ;
Binder, A .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2000, 1499 (1-2) :1-10
[5]  
Cakmak Seray Kulcu, 2012, Inflammation & Allergy Drug Targets, V11, P422
[6]   Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases [J].
Chen, YM ;
Lin, SL ;
Chiang, WC ;
Wu, DK ;
Tsai, TJ .
KIDNEY INTERNATIONAL, 2006, 69 (08) :1410-1415
[7]   Chemokines in Renal Injury [J].
Chung, Arthur C. K. ;
Lan, Hui Y. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 22 (05) :802-809
[8]   Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion [J].
Cugini, D ;
Azzollini, N ;
Gagliardini, E ;
Cassis, P ;
Bertini, R ;
Colotta, F ;
Noris, M ;
Remuzzi, G ;
Benigni, A .
KIDNEY INTERNATIONAL, 2005, 67 (05) :1753-1761
[9]   Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial [J].
Goicoechea, Marian ;
Garcia de Vinuesa, Soledad ;
Quiroga, Borja ;
Verdalles, Ursula ;
Barraca, Daniel ;
Yuste, Claudia ;
Panizo, Nayara ;
Verde, Eduardo ;
Angeles Munoz, M. ;
Luno, Jose .
JOURNAL OF NEPHROLOGY, 2012, 25 (06) :969-975
[10]   Pentoxifylline diminished acetaldehyde-induced collagen production in hepatic stellate cells by decreasing interleukin-6 expression [J].
Hernández, E ;
Correa, A ;
Bucio, L ;
Souza, V ;
Kershenobich, D ;
Gutiérrez-Ruiz, MC .
PHARMACOLOGICAL RESEARCH, 2002, 46 (05) :435-443